Loading…
Reported covered position: Chief of Staff, Rep. Roscoe Bartlett
How to read the money
Income and expense are whole-filing amounts associated with this lobbyist, not personal compensation or an allocated share.
No topic inference: each bill number appears in source LDA issue text assigned to this lobbyist.
Pandemic and All Hazards Preparedness Act, FY24 LHHS Funding for MCM Development; H.R.2940/S.1355.PASTEUR Act of 2023
Pandemic and All Hazards Preparedness Act, FY24 LHHS Funding for MCM Development; H.R.2940/S.1355.PASTEUR Act of 2023
Specific issues are shown only where the LDA source assigned them to this lobbyist. Targets apply to the associated filing.
TONIX PHARMACEUTICALS HOLDING CORP. via BURRELL INTERNATIONAL GROUP LLC
2026 · third_quarter · Q3
LHHS Appropriation R&D Funding, Pandemic Preparedness Funding for Next Generation Products; FY27 Defense Appropriation for broad-spectrum antivirals, FY27 FDA-AG for cocaine overdose funding; Alternative to Pain Act and Chronic Pain coverage
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
STEER TECH via BURRELL INTERNATIONAL GROUP LLC
2026 · third_quarter · Q3
Source: Senate LDA
| ERVIN GRAVES STRATEGY LLC ON BEHALF OF BYHEART INC |
| 25 |
| 2020–2025 |
| OXYGENIUM INC. | 22 | 2021–2026 |
| ACER THERAPEUTICS | 21 | 2019–2023 |
| APCO WORLDWIDE LLC (ON BEHALF OF QUIDELORTHO) | 20 | 2022–2026 |
| PACIFIC TECHNOLOGIES AND SOLUTIONS | 19 | 2022–2026 |
| SHIONOGI INC. | 19 | 2022–2026 |
| TONIX PHARMACEUTICALS HOLDING CORP. | 19 | 2022–2026 |
| BIOFACTURA INC | 16 | 2015–2026 |
| EMERGENT BIOSOLUTIONS INC (F/K/A ADAPT PHARMA INC ) | 16 | 2016–2019 |
| DYNAMIC INFRASTRUCTURE | 14 | 2019–2022 |
| ERVIN GRAVES STRATEGY ON BEHALF OF LYNDRA THERAPEUTICS FKA ERVIN HILL STRATEGY | 14 | 2019–2022 |
| O'BRIEN GENTRY & SCOTT LLC (ON BEHALF OF DSG TECHNOLOGY) | 13 | 2021–2023 |
| O'BRIEN GENTRY & SCOTT LLC (ON BEHALF OF Q30 INNOVATIONS LLC) | 13 | 2021–2023 |
| C2 STRATEGIES (ON BEHALF OF TACTICAL LIGHTING SYSTEMS) | 12 | 2024–2026 |
| GARWOOD MEDICAL DEVICES LLC | 12 | 2022–2024 |
| AVALO THERAPEUTICS | 11 | 2021–2023 |
| SMALL BIOTECHNOLOGY BUSINESS COALITION | 11 | 2019–2022 |
| HEMEMICS BIOTECHNOLOGIES, INC | 9 | 2020–2023 |
| HOMOLOGY MEDICINES | 9 | 2020–2022 |
| COGWEAR, INC | 8 | 2025–2026 |
| SESAME ENABLE, INC | 8 | 2017–2018 |
| SIGNATURE PERFORMANCE, INC. | 8 | 2025–2026 |
| ARSENAL MEDICAL, INC. | 7 | 2023–2024 |
| C2 STRATEGIES (O/B/O ARES SECURITY CORPORATION) | 7 | 2025–2026 |
| ERVIN GRAVES STRATEGY ON BEHALF OF GREFFEX INC. | 7 | 2020–2021 |
| OTOGENETICS | 7 | 2023–2024 |
| METEORIC RESOURCES NL | 6 | 2025–2026 |
| OBRIEN GENTRY & SCOTT LLC (ON BEHALF OF ELTA N.A.) | 6 | 2022–2023 |
| AMO PHARMA, LTD. | 5 | 2025–2026 |
| THE CONAFAY GROUP LLC O/B/O REALTA LIFE SCIENCES, INC | 5 | 2024–2025 |
| APCO WORLDWIDE LLC (ON BEHALF OF DETECTNOW F/K/A HOMODEUS DETECT) ) | 4 | 2020–2021 |
| APCO WORLDWIDE LLC (ON BEHALF OF HIKMA PHARMACEUTICALS USA INC.) | 4 | 2026 |
| CIVALA, INC. | 4 | 2026 |
| SENTRY VIEW SYSTEMS, INC. | 4 | 2026 |
| ABRAWORKS LIMITED | 3 | 2026 |
| ENGINUITY POWER SYSTEMS | 3 | 2024 |
| FLOWPAY CORPORATION | 3 | 2014–2015 |
| ANTARES PHARMA, INC. | 2 | 2026 |
| C2 STRATEGIES (ON BEHALF OF BC3 TECHNOLOGIES INC.) | 2 | 2026 |
| ERVIN GRAVES STRATEGY LLC ON BEHALF OF IMMUNICOM INC | 2 | 2020 |
| FAMAMEDIC, INC. | 2 | 2026 |
| THE CONAFAY GROUP LLC O/B/O SIGNATURE PERFORMANCE, INC | 1 | 2025 |
Pandemic and All Hazards Preparedness Act, FY24 LHHS Funding for MCM Development; H.R.2940/S.1355.PASTEUR Act of 2023
Pandemic and All Hazards Preparedness Act, FY24 LHHS Funding for MCM Development; H.R.2940/S.1355.PASTEUR Act of 2023
Pandemic and All Hazards Preparedness Act, FY24 LHHS Funding for MCM Development; H.R.2940/S.1355.PASTEUR Act of 2023
Pandemic and All Hazards Preparedness Act, FY24 LHHS Funding for MCM Development; H.R.2940/S.1355.PASTEUR Act of 2023
Pandemic preparedness; Antimicrobial resistance; PASTEUR Act (H.R. 3932 and S. 2076)
Pandemic preparedness; Antimicrobial resistance; PASTEUR Act (H.R. 3932 and S. 2076)
Pandemic preparedness; Antimicrobial resistance; PASTEUR Act (H.R. 3932 and S. 2076)
Pandemic preparedness; Antimicrobial resistance; PASTEUR Act (H.R. 3932 and S. 2076)
Medical Nutrition Equity Act of 2019
Client: HOMOLOGY MEDICINES · Firm: BURRELL INTERNATIONAL GROUP LLC
Drug pricing, gene therapy, and rare disease funding generally; H.R. 4393 - Advancing Access to Precision Medicine; H.R. 2507/S. 2158 Newborn Screening Saves Lives Reauthorization Act; H.R. 8045 - Genome Editing Threat Assessment Act; HR 2501 - Medical Nutrition Equity Act;
Medical Nutrition Equity Act of 2019
Client: HOMOLOGY MEDICINES · Firm: BURRELL INTERNATIONAL GROUP LLC
Drug pricing and gene therapy, generally; H.R. 4393 - Advancing Access to Precision Medicine; H.R. 2507/S. 2158 Newborn Screening Saves Lives Reauthorization Act; H.R. 8045 - Genome Editing Threat Assessment Act; HR 2501 - Medical Nutrition Equity Act;
Newborn Screening Saves Lives Reauthorization Act of 2019
Client: HOMOLOGY MEDICINES · Firm: BURRELL INTERNATIONAL GROUP LLC
Drug pricing, gene therapy, and rare disease funding generally; H.R. 4393 - Advancing Access to Precision Medicine; H.R. 2507/S. 2158 Newborn Screening Saves Lives Reauthorization Act; H.R. 8045 - Genome Editing Threat Assessment Act; HR 2501 - Medical Nutrition Equity Act;
Newborn Screening Saves Lives Reauthorization Act of 2019
Client: HOMOLOGY MEDICINES · Firm: BURRELL INTERNATIONAL GROUP LLC
Drug pricing and gene therapy, generally; H.R. 4393 - Advancing Access to Precision Medicine; H.R. 2507/S. 2158 Newborn Screening Saves Lives Reauthorization Act; H.R. 8045 - Genome Editing Threat Assessment Act; HR 2501 - Medical Nutrition Equity Act;
Advancing Access to Precision Medicine Act
Client: HOMOLOGY MEDICINES · Firm: BURRELL INTERNATIONAL GROUP LLC
Drug pricing and gene therapy, generally; H.R. 4393 - Advancing Access to Precision Medicine; H.R. 2507/S. 2158 Newborn Screening Saves Lives Reauthorization Act; H.R. 8045 - Genome Editing Threat Assessment Act; HR 2501 - Medical Nutrition Equity Act;
Advancing Access to Precision Medicine Act
Client: HOMOLOGY MEDICINES · Firm: BURRELL INTERNATIONAL GROUP LLC
Drug pricing, gene therapy, and rare disease funding generally; H.R. 4393 - Advancing Access to Precision Medicine; H.R. 2507/S. 2158 Newborn Screening Saves Lives Reauthorization Act; H.R. 8045 - Genome Editing Threat Assessment Act; HR 2501 - Medical Nutrition Equity Act;
Genome Editing Threat Assessment Act
Client: HOMOLOGY MEDICINES · Firm: BURRELL INTERNATIONAL GROUP LLC
Drug pricing and gene therapy, generally; H.R. 4393 - Advancing Access to Precision Medicine; H.R. 2507/S. 2158 Newborn Screening Saves Lives Reauthorization Act; H.R. 8045 - Genome Editing Threat Assessment Act; HR 2501 - Medical Nutrition Equity Act;
Genome Editing Threat Assessment Act
Client: HOMOLOGY MEDICINES · Firm: BURRELL INTERNATIONAL GROUP LLC
Drug pricing, gene therapy, and rare disease funding generally; H.R. 4393 - Advancing Access to Precision Medicine; H.R. 2507/S. 2158 Newborn Screening Saves Lives Reauthorization Act; H.R. 8045 - Genome Editing Threat Assessment Act; HR 2501 - Medical Nutrition Equity Act;
The Newborn Screening Saves Lives Reauthorization Act of 2019
Client: HOMOLOGY MEDICINES · Firm: BURRELL INTERNATIONAL GROUP LLC
Drug pricing and gene therapy, generally; H.R. 4393 - Advancing Access to Precision Medicine; H.R. 2507/S. 2158 Newborn Screening Saves Lives Reauthorization Act; H.R. 8045 - Genome Editing Threat Assessment Act; HR 2501 - Medical Nutrition Equity Act;
The Newborn Screening Saves Lives Reauthorization Act of 2019
Client: HOMOLOGY MEDICINES · Firm: BURRELL INTERNATIONAL GROUP LLC
Drug pricing, gene therapy, and rare disease funding generally; H.R. 4393 - Advancing Access to Precision Medicine; H.R. 2507/S. 2158 Newborn Screening Saves Lives Reauthorization Act; H.R. 8045 - Genome Editing Threat Assessment Act; HR 2501 - Medical Nutrition Equity Act;
Continuing Appropriations Amendments Act, 2018
Client: GRADIENT TECHNOLOGY · Firm: BURRELL INTERNATIONAL GROUP LLC
RDTE Appropriations and FY 2018 DoD Authorizations for client's products and services; National Defense Authorization Act and Defense Appropriation Bills, H.R.1301 - Department of Defense Appropriations Act, and H.R. 2810 - National Defense Authorization Act for Fiscal Year 2018; Funding in drafts of the FY 2019 Defense Authorization and Appropriations; H.R.5515/s. 2987 - John S. McCain National Defense Authorization Act for Fiscal Year 2019; H.R.6157 - Department of Defense Appropriations Act, 2019
Continuing Appropriations Amendments Act, 2018
Client: GRADIENT TECHNOLOGY · Firm: BURRELL INTERNATIONAL GROUP LLC
RDTE Appropriations and FY 2018 DoD Authorizations for client's products and services; National Defense Authorization Act and Defense Appropriation Bills, H.R.1301 - Department of Defense Appropriations Act, and H.R. 2810 - National Defense Authorization Act for Fiscal Year 2018.
National Defense Authorization Act for Fiscal Year 2018
Client: GRADIENT TECHNOLOGY · Firm: BURRELL INTERNATIONAL GROUP LLC
RDTE Appropriations and FY 2018 DoD Authorizations for client's products and services; National Defense Authorization Act and Defense Appropriation Bills, H.R.1301 - Department of Defense Appropriations Act, and H.R. 2810 - National Defense Authorization Act for Fiscal Year 2018; Funding in drafts of the FY 2019 Defense Authorization and Appropriations; H.R.5515/s. 2987 - John S. McCain National Defense Authorization Act for Fiscal Year 2019; H.R.6157 - Department of Defense Appropriations Act, 2019
National Defense Authorization Act for Fiscal Year 2018
Client: GRADIENT TECHNOLOGY · Firm: BURRELL INTERNATIONAL GROUP LLC
RDTE Appropriations and FY 2018 DoD Authorizations for client's products and services; National Defense Authorization Act and Defense Appropriation Bills, H.R.1301 - Department of Defense Appropriations Act, and H.R. 2810 - National Defense Authorization Act for Fiscal Year 2018.
John S. McCain National Defense Authorization Act for Fiscal Year 2019
Client: GRADIENT TECHNOLOGY · Firm: BURRELL INTERNATIONAL GROUP LLC
RDTE Appropriations and FY 2018 DoD Authorizations for client's products and services; National Defense Authorization Act and Defense Appropriation Bills, H.R.1301 - Department of Defense Appropriations Act, and H.R. 2810 - National Defense Authorization Act for Fiscal Year 2018; Funding in drafts of the FY 2019 Defense Authorization and Appropriations; H.R.5515/s. 2987 - John S. McCain National Defense Authorization Act for Fiscal Year 2019; H.R.6157 - Department of Defense Appropriations Act, 2019
Opioid Addiction Action Plan Act
Client: EMERGENT BIOSOLUTIONS INC (F/K/A ADAPT PHARMA INC ) · Firm: BURRELL INTERNATIONAL GROUP LLC
House and Senate Opioid Packages: H.R.6 - 115th Congress (2017-2018) SUPPORT for Patients and Communities Act; S.3120 - 115th Congress (2017-2018) HEAL Act of 2018; H.R.5925 - 115th Congress (2017-2018) CRISIS Act; H.R.5590 - 115th Congress (2017-2018) Opioid Addiction Action Plan Act; H.R.5774 - 115th Congress (2017-2018) Combating Opioid Abuse for Care in Hospitals Act of 2018; Naloxone access provisions, generally; Naloxone access provisions in S.3158, Labor/HHS appropriations bill
COACH Act of 2018
Client: EMERGENT BIOSOLUTIONS INC (F/K/A ADAPT PHARMA INC ) · Firm: BURRELL INTERNATIONAL GROUP LLC
House and Senate Opioid Packages: H.R.6 - 115th Congress (2017-2018) SUPPORT for Patients and Communities Act; S.3120 - 115th Congress (2017-2018) HEAL Act of 2018; H.R.5925 - 115th Congress (2017-2018) CRISIS Act; H.R.5590 - 115th Congress (2017-2018) Opioid Addiction Action Plan Act; H.R.5774 - 115th Congress (2017-2018) Combating Opioid Abuse for Care in Hospitals Act of 2018; Naloxone access provisions, generally; Naloxone access provisions in S.3158, Labor/HHS appropriations bill
Coordinated Response through Interagency Strategy and Information Sharing Act
Client: EMERGENT BIOSOLUTIONS INC (F/K/A ADAPT PHARMA INC ) · Firm: BURRELL INTERNATIONAL GROUP LLC
House and Senate Opioid Packages: H.R.6 - 115th Congress (2017-2018) SUPPORT for Patients and Communities Act; S.3120 - 115th Congress (2017-2018) HEAL Act of 2018; H.R.5925 - 115th Congress (2017-2018) CRISIS Act; H.R.5590 - 115th Congress (2017-2018) Opioid Addiction Action Plan Act; H.R.5774 - 115th Congress (2017-2018) Combating Opioid Abuse for Care in Hospitals Act of 2018; Naloxone access provisions, generally; Naloxone access provisions in S.3158, Labor/HHS appropriations bill
SUPPORT for Patients and Communities Act
Client: EMERGENT BIOSOLUTIONS INC (F/K/A ADAPT PHARMA INC ) · Firm: BURRELL INTERNATIONAL GROUP LLC
HR 6, Labor HHS Appropriations; CARA 2.0; POWER Act; Naloxone access provisions, generally; Opioid Package, issues relating to: naloxone access, coprescribing/opioid prescribing guidelines, Judiciary, Appropriations, Energy and Commerce, and Senate HELP provisions, generally.
SUPPORT for Patients and Communities Act
Client: EMERGENT BIOSOLUTIONS INC (F/K/A ADAPT PHARMA INC ) · Firm: BURRELL INTERNATIONAL GROUP LLC
HR 6, Labor HHS Appropriations; CARA 2.0; POWER Act; Naloxone access provisions, generally; Opioid Package, issues relating to: naloxone access, coprescribing/opioid prescribing guidelines, Judiciary, Appropriations, Energy and Commerce, and Senate HELP provisions, generally.
SUPPORT for Patients and Communities Act
Client: EMERGENT BIOSOLUTIONS INC (F/K/A ADAPT PHARMA INC ) · Firm: BURRELL INTERNATIONAL GROUP LLC
House and Senate Opioid Packages: H.R.6 - 115th Congress (2017-2018) SUPPORT for Patients and Communities Act; S.3120 - 115th Congress (2017-2018) HEAL Act of 2018; H.R.5925 - 115th Congress (2017-2018) CRISIS Act; H.R.5590 - 115th Congress (2017-2018) Opioid Addiction Action Plan Act; H.R.5774 - 115th Congress (2017-2018) Combating Opioid Abuse for Care in Hospitals Act of 2018; Naloxone access provisions, generally; Naloxone access provisions in S.3158, Labor/HHS appropriations bill
Department of Defense and Labor, Health and Human Services, and Education Appropriations Act, 2019 and Continuing Appropriations Act, 2019
Client: GRADIENT TECHNOLOGY · Firm: BURRELL INTERNATIONAL GROUP LLC
RDTE Appropriations and FY 2018 DoD Authorizations for client's products and services; National Defense Authorization Act and Defense Appropriation Bills, H.R.1301 - Department of Defense Appropriations Act, and H.R. 2810 - National Defense Authorization Act for Fiscal Year 2018; Funding in drafts of the FY 2019 Defense Authorization and Appropriations; H.R.5515/s. 2987 - John S. McCain National Defense Authorization Act for Fiscal Year 2019; H.R.6157 - Department of Defense Appropriations Act, 2019
Pandemic and All-Hazards Preparedness and Advancing Innovation Act of 2018
Client: CELLPHIRE, INC. · Firm: BURRELL INTERNATIONAL GROUP LLC
NDAA/Appropriations for Defense - US Army Medical Research; Client services and products S.2852 / HR 6378 - Pandemic and All-Hazards Preparedness and Advancing Innovation Act of 2018;
Pandemic and All-Hazards Preparedness and Advancing Innovation Act of 2018
Client: CELLPHIRE, INC. · Firm: BURRELL INTERNATIONAL GROUP LLC
Blood supply and next generation blood products provisions related within the NDAA, Defense Appropriations and S2852/HR 6378 - Pandemic and All-Hazards Preparedness and Advancing Innovation Act of 2018 ("PAHPA).
Pandemic and All-Hazards Preparedness and Advancing Innovation Act of 2018
Client: CELLPHIRE, INC. · Firm: BURRELL INTERNATIONAL GROUP LLC
Blood supply and next generation blood products provisions related within the NDAA, Defense Appropriations and S2852/HR 6378 - Pandemic and All-Hazards Preparedness and Advancing Innovation Act of 2018 ("PAHPA).
Pandemic and All-Hazards Preparedness and Advancing Innovation Act of 2018
Client: CELLPHIRE, INC. · Firm: BURRELL INTERNATIONAL GROUP LLC
NDAA/Appropriations for Defense - US Army Medical Research; Client services and products S.2852 / HR 6378 - Pandemic and All-Hazards Preparedness and Advancing Innovation Act of 2018;
Pandemic and All-Hazards Preparedness and Advancing Innovation Act of 2018
Client: CELLPHIRE, INC. · Firm: BURRELL INTERNATIONAL GROUP LLC
Blood supply and next generation blood products provisions related within the NDAA, Defense Appropriations and S2852/HR 6378 - Pandemic and All-Hazards Preparedness and Advancing Innovation Act of 2018 ("PAHPA).
Pandemic and All-Hazards Preparedness and Advancing Innovation Act of 2018
Client: CELLPHIRE, INC. · Firm: BURRELL INTERNATIONAL GROUP LLC
Blood supply and next generation blood products provisions related within the NDAA, Defense Appropriations and S2852/HR 6378 - Pandemic and All-Hazards Preparedness and Advancing Innovation Act of 2018 ("PAHPA).
John S. McCain National Defense Authorization Act for Fiscal Year 2019
Client: GRADIENT TECHNOLOGY · Firm: BURRELL INTERNATIONAL GROUP LLC
RDTE Appropriations and FY 2018 DoD Authorizations for client's products and services; National Defense Authorization Act and Defense Appropriation Bills, H.R.1301 - Department of Defense Appropriations Act, and H.R. 2810 - National Defense Authorization Act for Fiscal Year 2018; Funding in drafts of the FY 2019 Defense Authorization and Appropriations; H.R.5515/s. 2987 - John S. McCain National Defense Authorization Act for Fiscal Year 2019; H.R.6157 - Department of Defense Appropriations Act, 2019
HEAL Act of 2018
Client: EMERGENT BIOSOLUTIONS INC (F/K/A ADAPT PHARMA INC ) · Firm: BURRELL INTERNATIONAL GROUP LLC
House and Senate Opioid Packages: H.R.6 - 115th Congress (2017-2018) SUPPORT for Patients and Communities Act; S.3120 - 115th Congress (2017-2018) HEAL Act of 2018; H.R.5925 - 115th Congress (2017-2018) CRISIS Act; H.R.5590 - 115th Congress (2017-2018) Opioid Addiction Action Plan Act; H.R.5774 - 115th Congress (2017-2018) Combating Opioid Abuse for Care in Hospitals Act of 2018; Naloxone access provisions, generally; Naloxone access provisions in S.3158, Labor/HHS appropriations bill
Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2019
Client: EMERGENT BIOSOLUTIONS INC (F/K/A ADAPT PHARMA INC ) · Firm: BURRELL INTERNATIONAL GROUP LLC
House and Senate Opioid Packages: H.R.6 - 115th Congress (2017-2018) SUPPORT for Patients and Communities Act; S.3120 - 115th Congress (2017-2018) HEAL Act of 2018; H.R.5925 - 115th Congress (2017-2018) CRISIS Act; H.R.5590 - 115th Congress (2017-2018) Opioid Addiction Action Plan Act; H.R.5774 - 115th Congress (2017-2018) Combating Opioid Abuse for Care in Hospitals Act of 2018; Naloxone access provisions, generally; Naloxone access provisions in S.3158, Labor/HHS appropriations bill
Continuing Appropriations Amendments Act, 2018
Client: GRADIENT TECHNOLOGY · Firm: BURRELL INTERNATIONAL GROUP LLC
RDTE Appropriations and FY 2018 DoD Authorizations for client's products and services; National Defense Authorization Act and Defense Appropriation Bills, H.R.1301 - Department of Defense Appropriations Act, and H.R. 2810 - National Defense Authorization Act for Fiscal Year 2018.
Continuing Appropriations Amendments Act, 2018
Client: GRADIENT TECHNOLOGY · Firm: BURRELL INTERNATIONAL GROUP LLC
RDTE Appropriations and FY 2018 DoD Authorizations for client's products and services; National Defense Authorization Act and Defense Appropriation Bills, H.R.1301 - Department of Defense Appropriations Act, and H.R. 2810 - National Defense Authorization Act for Fiscal Year 2018.
Continuing Appropriations Amendments Act, 2018
Client: GRADIENT TECHNOLOGY · Firm: BURRELL INTERNATIONAL GROUP LLC
RDTE Appropriations and FY 2018 DoD Authorizations for client's products and services; National Defense Authorization Act and Defense Appropriation Bills, H.R.1301 - Department of Defense Appropriations Act, and H.R. 2810 - National Defense Authorization Act for Fiscal Year 2018.
National Defense Authorization Act for Fiscal Year 2018
Client: GRADIENT TECHNOLOGY · Firm: BURRELL INTERNATIONAL GROUP LLC
RDTE Appropriations and FY 2018 DoD Authorizations for client's products and services; National Defense Authorization Act and Defense Appropriation Bills, H.R.1301 - Department of Defense Appropriations Act, and H.R. 2810 - National Defense Authorization Act for Fiscal Year 2018.
National Defense Authorization Act for Fiscal Year 2018
Client: GRADIENT TECHNOLOGY · Firm: BURRELL INTERNATIONAL GROUP LLC
RDTE Appropriations and FY 2018 DoD Authorizations for client's products and services; National Defense Authorization Act and Defense Appropriation Bills, H.R.1301 - Department of Defense Appropriations Act, and H.R. 2810 - National Defense Authorization Act for Fiscal Year 2018.
National Defense Authorization Act for Fiscal Year 2018
Client: GRADIENT TECHNOLOGY · Firm: BURRELL INTERNATIONAL GROUP LLC
RDTE Appropriations and FY 2018 DoD Authorizations for client's products and services; National Defense Authorization Act and Defense Appropriation Bills, H.R.1301 - Department of Defense Appropriations Act, and H.R. 2810 - National Defense Authorization Act for Fiscal Year 2018.
National Defense Authorization Act for Fiscal Year 2017
Client: BIOFACTURA, INC. · Firm: BURRELL INTERNATIONAL GROUP LLC
Defense Medical Appropriations; HR 4909, The National Defense Authorization Act, Innovations for Healthier Americans and Senate HELP on Medical Countermeasure; S.2055, The Medical Countermeasure Innovation Act of 2016.
Comprehensive Opioid Abuse Reduction Act of 2016
Client: EMERGENT BIOSOLUTIONS INC (F/K/A ADAPT PHARMA INC ) · Firm: BURRELL INTERNATIONAL GROUP LLC
HR 5046 and S 524 Conference Committee on opioid overdose reversal drug policy.
Comprehensive Opioid Abuse Reduction Act of 2016
Client: EMERGENT BIOSOLUTIONS INC (F/K/A ADAPT PHARMA INC ) · Firm: BURRELL INTERNATIONAL GROUP LLC
HR 5046 and S 524 Conference Committee on opioid overdose reversal drug policy.
Comprehensive Opioid Abuse Reduction Act of 2016
Client: EMERGENT BIOSOLUTIONS INC (F/K/A ADAPT PHARMA INC ) · Firm: BURRELL INTERNATIONAL GROUP LLC
HR 5046 and S 524 Conference Committee on opioid overdose reversal drug policy.
Medical Countermeasure Innovation Act of 2016
Client: BIOFACTURA, INC. · Firm: BURRELL INTERNATIONAL GROUP LLC
Defense Medical Innovations for Healthier Americans and S.2055, The Medical Countermeasure Innovation Act of 2016.
Medical Countermeasure Innovation Act of 2016
Client: BIOFACTURA, INC. · Firm: BURRELL INTERNATIONAL GROUP LLC
Defense Medical Appropriations; HR 4909, The National Defense Authorization Act, Innovations for Healthier Americans and Senate HELP on Medical Countermeasure; S.2055, The Medical Countermeasure Innovation Act of 2016.
Medical Countermeasure Innovation Act of 2016
Client: BIOFACTURA, INC. · Firm: BURRELL INTERNATIONAL GROUP LLC
Defense Medical Innovations for Healthier Americans and S.2055, The Medical Countermeasure Innovation Act of 2016.
Medical Countermeasure Innovation Act of 2016
Client: BIOFACTURA, INC. · Firm: BURRELL INTERNATIONAL GROUP LLC
Defense Medical Innovations for Healthier Americans and S.2055, The Medical Countermeasure Innovation Act of 2016.
Comprehensive Addiction and Recovery Act of 2016
Client: EMERGENT BIOSOLUTIONS INC (F/K/A ADAPT PHARMA INC ) · Firm: BURRELL INTERNATIONAL GROUP LLC
HR 5046 and S 524 Conference Committee on opioid overdose reversal drug policy.
Comprehensive Addiction and Recovery Act of 2016
Client: EMERGENT BIOSOLUTIONS INC (F/K/A ADAPT PHARMA INC ) · Firm: BURRELL INTERNATIONAL GROUP LLC
HR 5046 and S 524 Conference Committee on opioid overdose reversal drug policy.
Comprehensive Addiction and Recovery Act of 2016
Client: EMERGENT BIOSOLUTIONS INC (F/K/A ADAPT PHARMA INC ) · Firm: BURRELL INTERNATIONAL GROUP LLC
HR 5046 and S 524 Conference Committee on opioid overdose reversal drug policy.
National Defense Authorization Act for Fiscal Year 2016
Client: BIOFACTURA, INC. · Firm: BURRELL INTERNATIONAL GROUP LLC
H.R. 1735/S. 1356, FY16 National Defense Authorization Act, provisions relating to Defense Threat Reduction Agency for Medical Countermeasures Systems.
National Defense Authorization Act for Fiscal Year 2016
Client: BIOFACTURA, INC. · Firm: BURRELL INTERNATIONAL GROUP LLC
H.R. 1735/S. 1356, FY16 National Defense Authorization Act, provisions relating to Defense Threat Reduction Agency for Medical Countermeasures Systems.
Requested an amendment to the NDAA in full committee; Requested an amendment for the floor in Defense Appropriations.
Filing targets: HOUSE OF REPRESENTATIVES
SIGNATURE PERFORMANCE INC. via BURRELL INTERNATIONAL GROUP LLC
2026 · third_quarter · Q3
Defense Health Agency for Enterprise-wide Revenue Cycle Management, FY27 NDAA and FY27 Defense Appropriation for RCM
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
SHIONOGI INC. via BURRELL INTERNATIONAL GROUP LLC
2026 · third_quarter · Q3
FY27 Appropriations and policy for the Strategic National Stockpile, BARDA, and Industrial Base Management Supply Chain, Pandemic and All Hazards Preparedness Act (PAHPA), PASTEUR Act and MCM Development funding; AMR issues; PBS/SRF, and PRV and MCM voucher programs.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
SENTRY VIEW SYSTEMS, INC. via BURRELL INTERNATIONAL GROUP LLC
2026 · third_quarter · Q3
FY27 Defense funding for nuclear security and FY27 NDAA
Filing targets: Defense, Dept of (DOD), HOUSE OF REPRESENTATIVES, SENATE
PACIFIC TECHNOLOGIES AND SOLUTIONS via BURRELL INTERNATIONAL GROUP LLC
2026 · third_quarter · Q3
Defense Appropriations for Cyber and Mission Assurance, 8(a) Native Hawaiian Organization Policy, Rare earth mine and AUKUS
Filing targets: Commerce, Dept of (DOC), Defense, Dept of (DOD), HOUSE OF REPRESENTATIVES, SENATE, State, Dept of (DOS)
OXYGENIUM INC. via BURRELL INTERNATIONAL GROUP LLC
2026 · third_quarter · Q3
Funding for portable oxygen generation systems; FY27 Defense Appropriations
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
GRADIENT TECHNOLOGY via BURRELL INTERNATIONAL GROUP LLC
2026 · third_quarter · Q3
FY27 Defense Appropriations for munitions demilitarization, Defense Production Act, white phosphorus and chembio demilitarization; Domestic Chemical production
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
GOLDBELT INC. via BURRELL INTERNATIONAL GROUP LLC
2026 · third_quarter · Q3
NDAA and Defense Appropriations for Cyber-Security and small business 8(A) Program
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
FAMAMEDIC, INC. via BURRELL INTERNATIONAL GROUP LLC
2026 · third_quarter · Q3
Healthcare Product Research & Development
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
COGWEAR, INC via BURRELL INTERNATIONAL GROUP LLC
2026 · third_quarter · Q3
FY26 and FY27 Defense Appropriations and FY27 NDAA for medical device for warfighter brain health for CTE
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
CIVALA, INC. via BURRELL INTERNATIONAL GROUP LLC
2026 · third_quarter · Q3
Advocacy related to NIH and ARPA-H funding for treatment of ALS, Parkinsons disease, cancer, and schizophrenia.
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
CELLPHIRE, INC. via BURRELL INTERNATIONAL GROUP LLC
2026 · third_quarter · Q3
Pandemic and All Hazard Preparedness Act, FY27 LHHS and Defense Appropriations for next generation blood products; FY27 NDAA, FY27 LHHS and FY27 DoD Authorization and Appropriations for Freeze-dried platelet and next gen blood products
Filing targets: Defense, Dept of (DOD), HOUSE OF REPRESENTATIVES, SENATE
C2 STRATEGIES (ON BEHALF OF TACTICAL LIGHTING SYSTEMS) via BURRELL INTERNATIONAL GROUP LLC
2026 · third_quarter · Q3
FY27 Defense appropriation and FY27 NDAA for Air Force funding
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
C2 STRATEGIES (ON BEHALF OF COCOON) via BURRELL INTERNATIONAL GROUP LLC
2026 · third_quarter · Q3
National Guard Funding and Defense Appropriations; FY27 NDAA and FY27 Appropriations Air Force O&M
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
C2 STRATEGIES (ON BEHALF OF BC3 TECHNOLOGIES INC.) via BURRELL INTERNATIONAL GROUP LLC
2026 · third_quarter · Q3
Compression and Damage Control Resuscitation
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
C2 STRATEGIES (O/B/O AVLITE SYSTEMS) via BURRELL INTERNATIONAL GROUP LLC
2026 · third_quarter · Q3
Defense Policy & Acquisition; Homeland Security and USCG Modernization; Defense Appropriations.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
C2 STRATEGIES (O/B/O ARES SECURITY CORPORATION) via BURRELL INTERNATIONAL GROUP LLC
2026 · third_quarter · Q3
Lobbying activity around their NDAA request in filling out the VA Delegation request.
APCO WORLDWIDE LLC (ON BEHALF OF QUIDELORTHO) via BURRELL INTERNATIONAL GROUP LLC
2026 · third_quarter · Q3
Labor/HHS Appropriation - Warm Base and Flexible Contracting, SNS and BARDA Funding, OTC Test Coverage, PAHPA. Industrial Base Management & Supply Chain (IBMSC) Funding; FY26 Defense Appropriations for DHA funding and VA funding for laboratory equipment.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
APCO WORLDWIDE LLC (ON BEHALF OF HIKMA PHARMACEUTICALS USA INC.) via BURRELL INTERNATIONAL GROUP LLC
2026 · third_quarter · Q3
Policies, federal programs, and procurement related to access to affordable medicines and pharmaceutical supply chain.
ANTARES PHARMA, INC. via BURRELL INTERNATIONAL GROUP LLC
2026 · third_quarter · Q3
Testosterone replacement therapy; FY28 Defense Authorization and Appropriations.
AMO PHARMA, LTD. via BURRELL INTERNATIONAL GROUP LLC
2026 · third_quarter · Q3
Rare Disease Policy and FDA Policy
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ABRAWORKS LIMITED via BURRELL INTERNATIONAL GROUP LLC
2026 · third_quarter · Q3
Provide strategic government affairs counsel and legislative consulting services regarding defense authorization, appropriations, counter-UAS, and artificial intelligence (AI) matters.
FAMAMEDIC, INC. via BURRELL INTERNATIONAL GROUP LLC
2026 · third_quarter · RR
Womens health and OTC product development
ANTARES PHARMA, INC. via BURRELL INTERNATIONAL GROUP LLC
2026 · third_quarter · RR
Testosterone replacement therapy; FY28 Defense Authorization and Appropriations.
Testosterone replacement therapy; FY28 Defense Authorization and Appropriations.
C2 STRATEGIES (ON BEHALF OF BC3 TECHNOLOGIES INC.) via BURRELL INTERNATIONAL GROUP LLC
2026 · third_quarter · RR
Compression and Damage Control Resuscitation
Compression and Damage Control Resuscitation
Compression and Damage Control Resuscitation
METEORIC RESOURCES NL via BURRELL INTERNATIONAL GROUP LLC
2026 · third_quarter · 3T
Monitoring the Administration's rare earth investments.
TONIX PHARMACEUTICALS HOLDING CORP. via BURRELL INTERNATIONAL GROUP LLC
2026 · second_quarter · Q2
LHHS Appropriation R&D Funding, Pandemic Preparedness Funding for Next Generation Products; FY27 Defense Appropriation for broad-spectrum antivirals, FY27 FDA-AG for cocaine overdose funding; Alternative to Pain Act and Chronic Pain coverage
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
STEER TECH via BURRELL INTERNATIONAL GROUP LLC
2026 · second_quarter · Q2
Requested an amendment to the NDAA in full committee; Requested an amendment for the floor in Defense Appropriations.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE, Transportation, Dept of (DOT)
SIGNATURE PERFORMANCE INC. via BURRELL INTERNATIONAL GROUP LLC
2026 · second_quarter · Q2
Defense Health Agency for Enterprise-wide Revenue Cycle Management, FY27 NDAA and FY27 Defense Appropriation for RCM
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
SHIONOGI INC. via BURRELL INTERNATIONAL GROUP LLC
2026 · second_quarter · Q2
FY27 Appropriations and policy for the Strategic National Stockpile, BARDA, and Industrial Base Management Supply Chain, Pandemic and All Hazards Preparedness Act (PAHPA), PASTEUR Act and MCM Development funding; AMR issues; PBS/SRF, and PRV and MCM voucher programs.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
SENTRY VIEW SYSTEMS, INC. via BURRELL INTERNATIONAL GROUP LLC
2026 · second_quarter · Q2
FY27 Defense funding for nuclear security and FY27 NDAA
Filing targets: Defense, Dept of (DOD), HOUSE OF REPRESENTATIVES, SENATE
PACIFIC TECHNOLOGIES AND SOLUTIONS via BURRELL INTERNATIONAL GROUP LLC
2026 · second_quarter · Q2
Defense Appropriations for Cyber and Mission Assurance, 8(a) Native Hawaiian Organization Policy, Rare earth mine and AUKUS
Filing targets: Commerce, Dept of (DOC), Defense, Dept of (DOD), HOUSE OF REPRESENTATIVES, SENATE, State, Dept of (DOS)
OXYGENIUM INC. via BURRELL INTERNATIONAL GROUP LLC
2026 · second_quarter · Q2
Funding for portable oxygen generation systems; FY27 Defense Appropriations
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
METEORIC RESOURCES NL via BURRELL INTERNATIONAL GROUP LLC
2026 · second_quarter · Q2
Monitoring the Administration's rare earth investments.
GRADIENT TECHNOLOGY via BURRELL INTERNATIONAL GROUP LLC
2026 · second_quarter · Q2
FY26 and FY27 Defense Appropriations for munitions demilitarization, Defense Production Act, white phos and chembio demilitarization; Domestic Chemical production
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
GOLDBELT INC. via BURRELL INTERNATIONAL GROUP LLC
2026 · second_quarter · Q2
NDAA and Defense Appropriations for Cyber-Security and small business 8(A) Program
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
COGWEAR, INC via BURRELL INTERNATIONAL GROUP LLC
2026 · second_quarter · Q2
FY26 and FY27 Defense Appropriations and FY27 NDAA for medical device for warfighter brain health for CTE
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
CIVALA, INC. via BURRELL INTERNATIONAL GROUP LLC
2026 · second_quarter · Q2
Advocacy related to NIH and ARPA-H funding for treatment of ALS, Parkinsons disease, cancer, and schizophrenia.
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
CELLPHIRE, INC. via BURRELL INTERNATIONAL GROUP LLC
2026 · second_quarter · Q2
Pandemic and All Hazard Preparedness Act, FY27 LHHS and Defense Appropriations for next generation blood products; FY27 NDAA, FY27 LHHS and FY27 DoD Authorization and Appropriations for Freeze-dried platelet and next gen blood products
Filing targets: Defense, Dept of (DOD), HOUSE OF REPRESENTATIVES, SENATE
C2 STRATEGIES (ON BEHALF OF TACTICAL LIGHTING SYSTEMS) via BURRELL INTERNATIONAL GROUP LLC
2026 · second_quarter · Q2
FY27 Defense appropriation and FY27 NDAA for Air Force funding
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
C2 STRATEGIES (ON BEHALF OF COCOON) via BURRELL INTERNATIONAL GROUP LLC
2026 · second_quarter · Q2
National Guard Funding and Defense Appropriations; FY27 NDAA and FY27 Appropriations Air Force O&M
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
C2 STRATEGIES (O/B/O AVLITE SYSTEMS) via BURRELL INTERNATIONAL GROUP LLC
2026 · second_quarter · Q2
Defense Policy & Acquisition; Homeland Security and USCG Modernization; Defense Appropriations.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
C2 STRATEGIES (O/B/O ARES SECURITY CORPORATION) via BURRELL INTERNATIONAL GROUP LLC
2026 · second_quarter · Q2
Lobbying activity around their NDAA request in filling out the VA Delegation request.
APCO WORLDWIDE LLC (ON BEHALF OF QUIDELORTHO) via BURRELL INTERNATIONAL GROUP LLC
2026 · second_quarter · Q2
Labor/HHS Appropriation - Warm Base and Flexible Contracting, SNS and BARDA Funding, OTC Test Coverage, PAHPA. Industrial Base Management & Supply Chain (IBMSC) Funding; FY26 Defense Appropriations for DHA funding and VA funding for laboratory equipment.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
APCO WORLDWIDE LLC (ON BEHALF OF HIKMA PHARMACEUTICALS USA INC.) via BURRELL INTERNATIONAL GROUP LLC
2026 · second_quarter · Q2
Policies, federal programs, and procurement related to access to affordable medicines and pharmaceutical supply chain.
AMO PHARMA, LTD. via BURRELL INTERNATIONAL GROUP LLC
2026 · second_quarter · Q2
Rare Disease Policy and FDA Policy
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ABRAWORKS LIMITED via BURRELL INTERNATIONAL GROUP LLC
2026 · second_quarter · Q2
Provide strategic government affairs counsel and legislative consulting services regarding defense authorization, appropriations, counter-UAS, and artificial intelligence (AI) matters.
ABRAWORKS LIMITED via BURRELL INTERNATIONAL GROUP LLC
2026 · second_quarter · RR
Provide strategic government affairs counsel and legislative consulting services regarding defense authorization, appropriations, counter-UAS, and artificial intelligence (AI) matters.
APCO WORLDWIDE LLC (ON BEHALF OF HIKMA PHARMACEUTICALS USA INC.) via BURRELL INTERNATIONAL GROUP LLC
2026 · first_quarter · Q1
Policies, federal programs, and procurement related to access to affordable medicines and pharmaceutical supply chain.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
BIOFACTURA, INC. via BURRELL INTERNATIONAL GROUP LLC
2026 · first_quarter · Q1
Medical Countermeasure Development for Smallpox and FY26 LHHS Appropriation
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
APCO WORLDWIDE LLC (ON BEHALF OF HIKMA PHARMACEUTICALS USA INC.) via BURRELL INTERNATIONAL GROUP LLC
2026 · first_quarter · RR
Policies, federal programs, and procurement related to access to affordable medicines and pharmaceutical supply chain.
TONIX PHARMACEUTICALS HOLDING CORP. via BURRELL INTERNATIONAL GROUP LLC
2026 · first_quarter · Q1
LHHS Appropriation R&D Funding, Pandemic Preparedness Funding for Next Generation Products; FY27 Defense Appropriation for broad-spectrum antivirals, FY27 FDA-AG for cocaine overdose funding; Alternative to Pain Act and Chronic Pain coverage
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
STEER TECH via BURRELL INTERNATIONAL GROUP LLC
2026 · first_quarter · Q1
Automated Vehicle Policy and Transportation Policy for smart cities; FY26 and FY27 Defense Appropriations for automated vehicle technology development and automated vehicle policy
Filing targets: HOUSE OF REPRESENTATIVES, SENATE, Transportation, Dept of (DOT)
SIGNATURE PERFORMANCE INC. via BURRELL INTERNATIONAL GROUP LLC
2026 · first_quarter · Q1
Defense Health Agency for Enterprise-wide Revenue Cycle Management, FY27 NDAA and FY27 Defense Appropriation for RCM
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
SHIONOGI INC. via BURRELL INTERNATIONAL GROUP LLC
2026 · first_quarter · Q1
FY27 Appropriations and policy for the Strategic National Stockpile, BARDA, and Industrial Base Management Supply Chain, Pandemic and All Hazards Preparedness Act (PAHPA), PASTEUR Act and MCM Development funding; AMR issues; PBS/SRF, and PRV and MCM voucher programs.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
SENTRY VIEW SYSTEMS, INC. via BURRELL INTERNATIONAL GROUP LLC
2026 · first_quarter · Q1
FY27 Defense funding for nuclear security and FY27 NDAA
Filing targets: Defense, Dept of (DOD), HOUSE OF REPRESENTATIVES, SENATE
PACIFIC TECHNOLOGIES AND SOLUTIONS via BURRELL INTERNATIONAL GROUP LLC
2026 · first_quarter · Q1
Defense Appropriations for Cyber and Mission Assurance, 8(a) Native Hawaiian Organization Policy, Rare earth mine and AUKUS
Filing targets: Commerce, Dept of (DOC), Defense, Dept of (DOD), HOUSE OF REPRESENTATIVES, SENATE, State, Dept of (DOS)
OXYGENIUM INC. via BURRELL INTERNATIONAL GROUP LLC
2026 · first_quarter · Q1
Funding for portable oxygen generation systems; FY27 Defense Appropriations
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
METEORIC RESOURCES NL via BURRELL INTERNATIONAL GROUP LLC
2026 · first_quarter · Q1
AUKUS, Defense Production Act for funding on rare earth mineral mining and processing
Filing targets: Defense, Dept of (DOD), HOUSE OF REPRESENTATIVES, SENATE, State, Dept of (DOS)
GRADIENT TECHNOLOGY via BURRELL INTERNATIONAL GROUP LLC
2026 · first_quarter · Q1
FY26 and FY27 Defense Appropriations for munitions demilitarization, Defense Production Act, white phos and chembio demilitarization; Domestic Chemical production
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
GOLDBELT INC. via BURRELL INTERNATIONAL GROUP LLC
2026 · first_quarter · Q1
NDAA and Defense Appropriations for Cyber-Security and small business 8(A) Program
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
COGWEAR, INC via BURRELL INTERNATIONAL GROUP LLC
2026 · first_quarter · Q1
FY26 and FY27 Defense Appropriations and FY27 NDAA for medical device for warfighter brain health for CTE
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
CIVALA, INC. via BURRELL INTERNATIONAL GROUP LLC
2026 · first_quarter · Q1
Advocacy related to NIH and ARPA-H funding for treatment of ALS, Parkinsons disease, cancer, and schizophrenia.
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
CELLPHIRE, INC. via BURRELL INTERNATIONAL GROUP LLC
2026 · first_quarter · Q1
Pandemic and All Hazard Preparedness Act, FY27 LHHS and Defense Appropriations for next generation blood products; FY27 NDAA, FY27 LHHS and FY27 DoD Authorization and Appropriations for Freeze-dried platelet and next gen blood products
Filing targets: Defense, Dept of (DOD), HOUSE OF REPRESENTATIVES, SENATE
C2 STRATEGIES (ON BEHALF OF TACTICAL LIGHTING SYSTEMS) via BURRELL INTERNATIONAL GROUP LLC
2026 · first_quarter · Q1
FY27 Defense appropriation and FY27 NDAA for Air Force funding
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
C2 STRATEGIES (ON BEHALF OF COCOON) via BURRELL INTERNATIONAL GROUP LLC
2026 · first_quarter · Q1
National Guard Funding and Defense Appropriations; FY27 NDAA and FY27 Appropriations Air Force O&M
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
C2 STRATEGIES (O/B/O AVLITE SYSTEMS) via BURRELL INTERNATIONAL GROUP LLC
2026 · first_quarter · Q1
Defense Policy & Acquisition; Homeland Security and USCG Modernization; Defense Appropriations.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
C2 STRATEGIES (O/B/O ARES SECURITY CORPORATION) via BURRELL INTERNATIONAL GROUP LLC
2026 · first_quarter · Q1
Army Ground Vehicle Systems; FY26/FY27 Defense Appropriations for RDTE for GVSC Warfighter Machine Interface and related funding in the House and Senate Defense Appropriations legislation.
Filing targets: Army, Dept of (Other), HOUSE OF REPRESENTATIVES, SENATE
APCO WORLDWIDE LLC (ON BEHALF OF QUIDELORTHO) via BURRELL INTERNATIONAL GROUP LLC
2026 · first_quarter · Q1
Labor/HHS Appropriation - Warm Base and Flexible Contracting, SNS and BARDA Funding, OTC Test Coverage, PAHPA. Industrial Base Management & Supply Chain (IBMSC) Funding; FY26 Defense Appropriations for DHA funding and VA funding for laboratory equipment
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
AMO PHARMA, LTD. via BURRELL INTERNATIONAL GROUP LLC
2026 · first_quarter · Q1
Rare Disease Policy and FDA Policy
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
CIVALA, INC. via BURRELL INTERNATIONAL GROUP LLC
2026 · first_quarter · RR
Advocacy related to NIH and ARPA-H funding for treatment of ALS, Parkinsons disease, cancer, and schizophrenia.
SENTRY VIEW SYSTEMS, INC. via BURRELL INTERNATIONAL GROUP LLC
2026 · first_quarter · RR
Defense funding and FY27 NDAA
TONIX PHARMACEUTICALS HOLDING CORP. via BURRELL INTERNATIONAL GROUP LLC
2025 · fourth_quarter · Q4
LHHS Appropriation R&D Funding, Pandemic Preparedness Funding for Next Generation Products; FY26 Defense Appropriation for broad-spectrum antivirals, FY26 LHHS for Long COVID and cocaine overdose funding; Alternative to Pain Act and Chronic Pain coverage
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
THE CONAFAY GROUP LLC O/B/O REALTA LIFE SCIENCES, INC via BURRELL INTERNATIONAL GROUP LLC
2025 · fourth_quarter · 4T
Health, FDA issues related to Hypoxic Ischemic Encephalopathy "HIE."
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
STEER TECH via BURRELL INTERNATIONAL GROUP LLC
2025 · fourth_quarter · Q4
Automated Vehicle Policy and Transportation Policy for smart cities; FY26 Defense Appropriations for automated vehicle technology development and automated vehicle policy
Filing targets: HOUSE OF REPRESENTATIVES, SENATE, Transportation, Dept of (DOT)
SIGNATURE PERFORMANCE INC. via BURRELL INTERNATIONAL GROUP LLC
2025 · fourth_quarter · Q4
Defense Health Authorization for Enterprise-wide Revenue Cycle Management, FY26 NDAA, Defense Appropriation
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
SHIONOGI INC. via BURRELL INTERNATIONAL GROUP LLC
2025 · fourth_quarter · Q4
FY26 Appropriations and policy for the Strategic National Stockpile, BARDA, and Industrial Base Management Supply Chain, Pandemic and All Hazards Preparedness Act (PAHPA), PASTEUR Act and MCM Development funding; AMR issues.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
PACIFIC TECHNOLOGIES AND SOLUTIONS via BURRELL INTERNATIONAL GROUP LLC
2025 · fourth_quarter · Q4
Defense Appropriations for Cyber and Mission Assurance, 8(a) Native Hawaiian Organization Policy, Rare earth mining and AUKUS
Filing targets: Commerce, Dept of (DOC), Defense, Dept of (DOD), HOUSE OF REPRESENTATIVES, SENATE, State, Dept of (DOS)
OXYGENIUM INC. via BURRELL INTERNATIONAL GROUP LLC
2025 · fourth_quarter · Q4
Funding for portable oxygen generation systems; No specific legislation at this time.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
METEORIC RESOURCES NL via BURRELL INTERNATIONAL GROUP LLC
2025 · fourth_quarter · Q4
AUKUS, FY26 NDAA, Defense Production Act for funding on rare earth mineral mining and processing
Filing targets: Defense, Dept of (DOD), HOUSE OF REPRESENTATIVES, SENATE, State, Dept of (DOS)
GRADIENT TECHNOLOGY via BURRELL INTERNATIONAL GROUP LLC
2025 · fourth_quarter · Q4
FY26 Defense Appropriations for munitions demilitarization, Defense Production Act and chembio demilitarization; Domestic Chemical production
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
GOLDBELT INC. via BURRELL INTERNATIONAL GROUP LLC
2025 · fourth_quarter · Q4
NDAA and Defense Appropriations for Cyber-Security and small business 8(A) Program
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ERVIN GRAVES STRATEGY LLC ON BEHALF OF BYHEART INC via BURRELL INTERNATIONAL GROUP LLC
2025 · fourth_quarter · 4T
Generate advocacy for the expansion of domestic infant formula manufacturing; House and Senate Appropriations; FY26 AG Appropriations for infant formula manufacturing, and tax credit for domestic infant formula manufacturing; FDA and Domestic Infant Formula Manufacturing and Tax Credits
Availability of domestic supply chain materials, mother and baby nutrition; FY26 Appropriations and funding for mother and baby nutrition; FY26 AG Appropriations for infant formula manufacturing, and tax credit for domestic infant formula manufacturing; FDA and Domestic Infant Formula Manufacturing and Tax Credits
Filing targets: Agriculture, Dept of (USDA), HOUSE OF REPRESENTATIVES, SENATE
COGWEAR, INC via BURRELL INTERNATIONAL GROUP LLC
2025 · fourth_quarter · Q4
FY26 Defense Appropriations and FY26 NDAA for warfighter brain health for CTE
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
CELLPHIRE, INC. via BURRELL INTERNATIONAL GROUP LLC
2025 · fourth_quarter · Q4
Pandemic and All Hazard Preparedness Act, FY26 LHHS and Defense Appropriations for next generation blood products; FY26 NDAA, FY26 LHHS and FY26 DoD Authorization and Appropriations for Freeze-dried platelet and next gen blood products
Filing targets: Defense, Dept of (DOD), HOUSE OF REPRESENTATIVES, SENATE
C2 STRATEGIES (ON BEHALF OF TACTICAL LIGHTING SYSTEMS) via BURRELL INTERNATIONAL GROUP LLC
2025 · fourth_quarter · Q4
FY26 Defense appropriation and FY26 NDAA for Air Force funding
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
C2 STRATEGIES (ON BEHALF OF COCOON) via BURRELL INTERNATIONAL GROUP LLC
2025 · fourth_quarter · Q4
National Guard Funding and Defense Appropriations; FY26 Air Force O&M Funding
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
C2 STRATEGIES (O/B/O AVLITE SYSTEMS) via BURRELL INTERNATIONAL GROUP LLC
2025 · fourth_quarter · Q4
Defense Policy & Acquisition; Homeland Security and USCG Modernization; Defense Appropriations.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
C2 STRATEGIES (O/B/O ARES SECURITY CORPORATION) via BURRELL INTERNATIONAL GROUP LLC
2025 · fourth_quarter · Q4
Army Ground Vehicle Systems; FY26 Defense Appropriations for RDTE for GVSC Warfighter Machine Interface and related funding in the House and Senate Defense Appropriations legislation.
Filing targets: Army, Dept of (Other), HOUSE OF REPRESENTATIVES, SENATE
BIOFACTURA, INC. via BURRELL INTERNATIONAL GROUP LLC
2025 · fourth_quarter · Q4
Medical Countermeasure Development for Smallpox and FY26 LHHS Appropriation
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
APCO WORLDWIDE LLC (ON BEHALF OF QUIDELORTHO) via BURRELL INTERNATIONAL GROUP LLC
2025 · fourth_quarter · Q4
Labor/HHS Appropriation - Warm Base and Flexible Contracting, SNS and BARDA Funding, OTC Test Coverage, PAHPA. Industrial Base Management & Supply Chain (IBMSC) Funding; FY26 Defense Appropriations for DHA funding and VA funding for laboratory equipment
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
AMO PHARMA, LTD. via BURRELL INTERNATIONAL GROUP LLC
2025 · fourth_quarter · Q4
Rare Disease Policy and FDA Policy
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
METEORIC RESOURCES NL via BURRELL INTERNATIONAL GROUP LLC
2025 · third_quarter · Q3
AUKUS, FY26 NDAA, Defense Production Act for funding on rare earth mineral mining and processing
Filing targets: Defense, Dept of (DOD), HOUSE OF REPRESENTATIVES, SENATE, State, Dept of (DOS)
AMO PHARMA, LTD. via BURRELL INTERNATIONAL GROUP LLC
2025 · third_quarter · RR
Rare Disease Policy and FDA Policy
TONIX PHARMACEUTICALS HOLDING CORP. via BURRELL INTERNATIONAL GROUP LLC
2025 · third_quarter · Q3
LHHS Appropriation R&D Funding, Pandemic Preparedness Funding for Next Generation Products; FY26 Defense Appropriation for broad-spectrum antivirals, FY26 LHHS for Long COVID and cocaine overdose funding; Alternative to Pain Act and Chronic Pain coverage
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
THE CONAFAY GROUP LLC O/B/O REALTA LIFE SCIENCES, INC via BURRELL INTERNATIONAL GROUP LLC
2025 · third_quarter · Q3
Health, FDA issues related to Hypoxic Ischemic Encephalopathy "HIE."
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
STEER TECH via BURRELL INTERNATIONAL GROUP LLC
2025 · third_quarter · Q3
Automated Vehicle Policy and Transportation Policy for smart cities; FY26 Defense Appropriations for automated vehicle technology development and automated vehicle policy
Filing targets: HOUSE OF REPRESENTATIVES, SENATE, Transportation, Dept of (DOT)
SIGNATURE PERFORMANCE INC. via BURRELL INTERNATIONAL GROUP LLC
2025 · third_quarter · Q3
Defense Health Authorization for Revenue Cycle Management, FY26 NDAA
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
SHIONOGI INC. via BURRELL INTERNATIONAL GROUP LLC
2025 · third_quarter · Q3
FY26 Appropriations and policy for the Strategic National Stockpile, BARDA, and Industrial Base Management Supply Chain, Pandemic and All Hazards Preparedness Act (PAHPA), PASTEUR Act and MCM Development funding; AMR issues.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Compression and Damage Control Resuscitation